Xilio Therapeutics, Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

XLO

organization

SIC: 2834

SEC Insider

$66.4M

246 transactions

Summary

Xilio Therapeutics, Inc. (XLO) is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $56.4MSales: $18K51 insiders

Date	Insider	Type	Value
2026-02-13	GILEAD SCIENCES, INC.	Buy	$2.0M
2026-03-26	Shannon James Samuel	Buy	$44K
2026-01-02	Frankenfield Christopher James(Chief Financial Officer)	Sell	$4K
2026-01-02	Brennan Kevin M.(SVP, FINANCE AND ACCOUNTING)	Sell	$1K
2026-06-11	Brennan Aoife	A	$0
2026-06-11	Bonstein Sara	A	$0
2026-06-11	ROSS ROBERT W.	A	$0
2026-06-11	Xu Yuan	A	$0
2026-06-11	Bello Akintunde Olatokumbo	A	$0
2026-06-11	Shannon James Samuel	A	$0
2026-06-11	Curran Daniel J.	A	$0
2026-04-15	Blanchard Cheryl R	A	$0
2026-01-01	Russo Rene(PRESIDENT AND CEO)	M	$0
2026-01-01	Russo Rene(PRESIDENT AND CEO)	M	—
2026-01-01	Frankenfield Christopher James(Chief Financial Officer)	M	$0
2026-01-01	Frankenfield Christopher James(Chief Financial Officer)	M	—
2026-01-01	Brennan Kevin M.(SVP, FINANCE AND ACCOUNTING)	M	$0
2026-01-01	Brennan Kevin M.(SVP, FINANCE AND ACCOUNTING)	M	—
2026-01-01	Luptakova Katarina(CHIEF MEDICAL OFFICER)	M	$0
2026-01-01	Luptakova Katarina(CHIEF MEDICAL OFFICER)	M	—

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

Xilio Therapeutics, Inc. — Contributions, Lobbying & Contracts | Poliscope